论文部分内容阅读
公司加大国内制剂销售力度,预计下半年制剂药仍将保持快速增长。上半年公司因成本下降而增加毛利6800万元,预计全年可降本增利1.5亿元,较好覆盖原材料和能源等成本上升,因此下半年利润基数会远高于上半年。今日投资个股安全诊断星级:★★★★★
Companies to increase sales of domestic preparations, pharmaceutical preparations is expected in the second half will maintain rapid growth. In the first half of the year, the Company increased its gross profit of 68 million yuan due to the decrease of costs. It is estimated that the annual increase of profits and losses will be 150 million yuan, covering the cost increase of raw materials and energy so that the profit base in the second half of the year will be far higher than that in the first half of the year. Today, investment stocks safety diagnosis star: ★ ★ ★ ★ ★